AZD0865, also known as Linaprazan, is primarily investigated for its potential in treating acid-related disorders. It functions as a potassium-competitive acid blocker (P-CAB), which makes it effective in reducing gastric acid secretion. This mechanism is particularly beneficial for managing conditions like gastroesophageal reflux disease (GERD) and peptic ulcers. Its rapid onset of action and prolonged effect offer an advantage over traditional proton pump inhibitors (PPIs), providing quicker relief and potentially better control of symptoms. Additionally, it is being explored for its efficacy in Helicobacter pylori eradication therapy, often in combination with antibiotics, to enhance treatment outcomes. The compound's unique properties make it a promising candidate for improving the management of acid-related gastrointestinal conditions.